The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biochemical Insights into Progeria Syndrome Identify Bisphosphonates, Statins as Possible Candidate Drugs to Halt Aging

Biochemical Insights into Progeria Syndrome Identify Bisphosphonates, Statins as Possible Candidate Drugs to Halt Aging

August 10, 2016 • By Simon M. Helfgott, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Can We Stay Forever Young?
May your heart always be joyful
And may your song always be sung
May you stay forever young
Forever Young —Bob Dylan

You Might Also Like
  • Telomere Length Provides Insights into Cartilage Aging and Repair
  • 2014 ACR/ARHP Annual Meeting: Telomeres and the Aging Immune System
  • 7 Tools to Identify Depression
Explore This Issue
August 2016
Also By This Author
  • When Sense Disorders Signal Immune System Interactions

Beneath the rubric of orphan diseases reside some rare conditions and others that are extraordinarily uncommon. These are the diseases that most physicians either never to get to see or may have the opportunity to observe only a single case in their career. Within this group resides one disease so exceptionally rare that one of the largest published case series describing those afflicted with this singular disorder listed more co-authors (25) than it did patients (15).1 It has been estimated that a mere 350 children worldwide suffer from this disorder, one so devastating because it mimics the aging process run amok. In fact, one movie, The Curious Case of Benjamin Button, starring Brad Pitt as a man who ages in reverse, touched on the emotional aspects of this illness.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Biology has advanced sufficiently to allow us to study the genomic details that shape an organism’s phenotype. Consider what happens when a single amino acid is switched from glycine GGC to glycine GGT in codon 608 of exon 11 in the lamin A (LMNA) gene. Instead of creating the code that produces lamin A, the fibrous protein responsible for providing structural function and transcriptional regulation in the cell nucleus, an aberrant protein, progerin, is manufactured instead.

Whereas lamin A is released by enzymatic cleavage and can harmlessly float away, progerin lacks this cleavage site and remains permanently anchored to the inner nuclear membrane, becoming an unwanted guest that wreaks molecular havoc with life-altering consequences. Progerin does everything wrong; it binds to the wrong proteins, it distorts the cell nucleus, it disrupts mitosis, and if this weren’t enough, it alters gene expression. The end result is the devastating Hutchinson–Gilford progeria syndrome, named after the two British practitioners who first described this illness in 1896 and 1897, respectively.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Progeria is one of 11 laminopathies caused by more than 180 known LMNA mutations that disturb or disrupt the nuclear envelope. Some are lethal, and others cause non-fatal, but serious, muscular and lipodystrophy syndromes. Cruel diseases all, but none so cruel as progeria, where a lifetime of aging is viciously compressed into a few decades of life. The affected child’s phenotype includes alopecia and sclerotic skin; bone growth abnormalities, including acro-osteolysis; hip, spine and clavicular anomalies; poor dentition; and a fatally accelerated aging of their heart and blood vessels, so that most affected children die from cardiovascular disease before they reach adolesence.1

Pages: 1 2 3 4 5 | Single Page

Filed Under: Career Development, Education & Training, Professional Topics Tagged With: aging, biochemical, bisphosphonates, Clinical, Drugs, patient care, progeria, Research, rheumatology, Statin, therapyIssue: August 2016

You Might Also Like:
  • Telomere Length Provides Insights into Cartilage Aging and Repair
  • 2014 ACR/ARHP Annual Meeting: Telomeres and the Aging Immune System
  • 7 Tools to Identify Depression
  • Do Bisphosphonates Increase Risk of Carpal Tunnel Syndrome?

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)